2. Academic Validation
  3. Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection

Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection

  • J Med Chem. 2014 Mar 13;57(5):1708-29. doi: 10.1021/jm401840s.
Paul M Scola 1,  Alan Xiangdong Wang,  Andrew C Good,  Li-Qiang Sun,  Keith D Combrink,  Jeffrey A Campbell,  Jie Chen,  Yong Tu,  Ny Sin,  Brian L Venables,  Sing-Yuen Sit,  Yan Chen,  Anthony Cocuzza,  Donna M Bilder,  Stanley D'Andrea,  Barbara Zheng,  Piyasena Hewawasam,  Min Ding,  Jan Thuring,  Jianqing Li,  Dennis Hernandez,  Fei Yu,  Paul Falk,  Guangzhi Zhai,  Amy K Sheaffer,  Chaoqun Chen,  Min S Lee,  Diana Barry,  Jay O Knipe,  Wenying Li,  Yong-Hae Han,  Susan Jenkins,  Christoph Gesenberg,  Qi Gao,  Michael W Sinz,  Kenneth S Santone,  Tatyana Zvyaga,  Ramkumar Rajamani,  Herbert E Klei,  Richard J Colonno,  Dennis M Grasela,  Eric Hughes,  Caly Chien,  Stephen Adams,  Paul C Levesque,  Danshi Li,  Jialong Zhu,  Nicholas A Meanwell,  Fiona McPhee
Affiliations

Affiliation

  • 1 Department of Discovery Chemistry, Bristol-Myers Squibb Research and Development , 5 Research Parkway, Wallingford, Connecticut 06492, United States.
PMID: 24555570 DOI: 10.1021/jm401840s
Abstract

The discovery of BMS-605339 (35), a tripeptidic inhibitor of the NS3/4A enzyme, is described. This compound incorporates a cyclopropylacylsulfonamide moiety that was designed to improve the potency of carboxylic acid prototypes through the introduction of favorable nonbonding interactions within the S1' site of the protease. The identification of 35 was enabled through the optimization and balance of critical properties including potency and pharmacokinetics (PK). This was achieved through modulation of the P2* subsite of the inhibitor which identified the isoquinoline ring system as a key template for improving PK properties with further optimization achieved through functionalization. A methoxy moiety at the C6 position of this isoquinoline ring system proved to be optimal with respect to potency and PK, thus providing the clinical compound 35 which demonstrated Antiviral activity in HCV-infected patients.

Figures
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z